# A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren

> **NCT03796637** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT03796637
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03796637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03796637, "A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03796637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*